Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

KalVista Pharmaceuticals (KALV) EBT Margin: 2014-2020

Historic EBT Margin for KalVista Pharmaceuticals (KALV) over the last 6 years, with Apr 2020 value amounting to -224.74%.

  • KalVista Pharmaceuticals' EBT Margin rose 14707.00% to -224.74% in Q2 2020 from the same period last year, while for Apr 2020 it was -305.00%, marking a year-over-year decrease of 12873.00%. This contributed to the annual value of 3,112.39% for FY2025, which is 336568.00% up from last year.
  • KalVista Pharmaceuticals' EBT Margin amounted to -224.74% in Q2 2020, which was up 71.31% from -783.26% recorded in Q1 2020.
  • KalVista Pharmaceuticals' EBT Margin's 5-year high stood at -60.00% during Q2 2018, with a 5-year trough of -94,342.86% in Q1 2016.
  • Moreover, its 3-year median value for EBT Margin was -205.10% (2018), whereas its average is -253.87%.
  • In the last 5 years, KalVista Pharmaceuticals' EBT Margin plummeted by 2,028,571bps in 2016 and then soared by 549,200bps in 2018.
  • Over the past 5 years, KalVista Pharmaceuticals' EBT Margin (Quarterly) stood at -2,038.07% in 2016, then surged by 151,136bps to -526.71% in 2017, then spiked by 44,286bps to -83.85% in 2018, then crashed by 14,023bps to -224.08% in 2019, then skyrocketed by 14,707bps to -224.74% in 2020.
  • Its EBT Margin was -224.74% in Q2 2020, compared to -783.26% in Q1 2020 and -224.08% in Q4 2019.